Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Lyfe Rx vs Omada Health

Lyfe Rx
Graded #375

Higher grade

vs+2.6999999999999957
Omada Health
Graded #435

Lower grade

The verdict

Lyfe Rx takes it — 58.3/100 to 55.6/100.

Lyfe Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lyfe Rx offers compounded semaglutide ($289) and compounded tirzepatide ($399).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLyfe Rx +5
50
45
Dose & formulationLyfe Rx +24
64
40
Clinical oversightOmada Health +10
67
77
Labs & monitoringOmada Health +9
52
61
FulfillmentEven
62
62
Contract termsEven
55
55
Lyfe Rx · left barOmada Health · right bar

The numbers

MetricLyfe RxOmada Health
WeighScore58.3/10055.6/100
GradeCC
Scorecard rank#375#435
Semaglutide$225/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Lyfe Rx

Graded #375 · C

Strengths

  • Both compounded semaglutide and tirzepatide available
  • Delivery to all 50 states with 1–3 day pharmacy turnaround

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • Also sells non-prescription supplements ('Tirzepatide Weight Loss Supplement', 'Lipo Burn')
  • Shopify-based e-commerce storefront — less clinical infrastructure
  • FDA issued this company a warning letter dated 9 September 2025; the letter is public in FDA's warning-letter database
Omada Health

Graded #435 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard